1-arabinofuranosylcytosine-5'-stearylphosphate profile

1-arabinofuranosylcytosine-5'-stearylphosphate (Ara-C-Stearyl Phosphate) is a synthetic analog of the antiviral drug cytarabine (Ara-C), also known as cytosine arabinoside.

**Here's what makes Ara-C-Stearyl Phosphate unique and important for research:**

* **Enhanced Delivery:** The addition of the stearyl phosphate group to Ara-C significantly improves its ability to penetrate cell membranes. This enhanced delivery mechanism makes Ara-C-Stearyl Phosphate a promising candidate for:
* **Targeted Drug Delivery:** It can be specifically delivered to target cells or tissues by incorporating the stearyl phosphate moiety into liposomes or other carrier systems.
* **Overcoming Drug Resistance:** Some cancer cells develop resistance to traditional chemotherapy drugs, including Ara-C. Ara-C-Stearyl Phosphate's enhanced delivery could circumvent these resistance mechanisms.

* **Potent Antitumor Activity:** Ara-C-Stearyl Phosphate retains the anticancer activity of Ara-C, acting as an inhibitor of DNA synthesis. This makes it a valuable tool for studying:
* **Cancer Biology:** Understanding the mechanisms of action and resistance of anticancer drugs.
* **New Treatment Strategies:** Developing novel therapies for various types of cancer.

* **Improved Pharmacokinetic Properties:** The stearyl phosphate group alters the pharmacokinetic profile of Ara-C, potentially leading to:
* **Longer Duration of Action:** Increased time the drug remains effective in the body.
* **Reduced Dosage Frequency:** Fewer administrations needed for therapeutic effect.

**Current Research Applications:**

* **Preclinical Studies:** Ara-C-Stearyl Phosphate is actively being studied in preclinical models (in vitro and in vivo) to evaluate its efficacy against various cancer types.
* **Drug Delivery Systems:** Researchers are investigating ways to incorporate Ara-C-Stearyl Phosphate into liposomes, nanoparticles, and other delivery systems to achieve targeted drug delivery.
* **Combination Therapies:** Exploring the potential of Ara-C-Stearyl Phosphate in combination with other anticancer agents to enhance therapeutic outcomes.

**Overall, Ara-C-Stearyl Phosphate is a promising drug candidate with the potential to overcome limitations of traditional Ara-C therapy. It offers researchers a valuable tool for exploring novel cancer treatment strategies and advancing the fight against this disease.**

1-arabinofuranosylcytosine-5'-stearylphosphate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	13491648
SCHEMBL ID	13524289
MeSH ID	M0169659

Synonym
1-arabinofuranosylcytosine-5'-stearylphosphate
SCHEMBL13524289
SY313379
[(2r,3s,4s,5r)-5-[4-amino-2-oxopyrimidin-1(2h)-yl]-3,4-dihydroxy-2-tetrahydrofuryl]methyl octadecyl hydrogen phosphate
mfcd31746875

Excerpt	Reference	Relevance
" During a phase I study in patients with advanced low-grade non-Hodgkin lymphomas or acute myeloid leukemia, the pharmacokinetic parameters of Ara-CMP-Stearate (kindly provided by ASTA Medica, Frankfurt, Germany) were determined by HPLC analysis."	( Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S, 1995)	0.29
" From all of pharmacokinetic data, the oral administration of SPAC at 150 to 300 mg/m2/day was pharmacokinetically concluded to be comparable to the continuous infusion of ara-C at 20 mg/m2/day."	( [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies]. Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y, 1998)	0.3
" Pharmacokinetic evaluations were performed during 34 treatment cycles in 28 patients."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3
"Provide pharmacokinetic data for orally administered CO and determine accumulation and functional consequences of Ara-CTP within peripheral blood leukocytes."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13

Excerpt	Reference	Relevance
"8% was absorbed and metabolized to AraC and AraU, defining the metabolic bioavailability of this prodrug."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3

Excerpt	Relevance	Reference
" The dosage for the single and 5-day oral administration ranged 50 to 1,200 and 100 to 900 mg/body/day, respectively."	( [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)]. Fukuoka, M; Hattori, M; Hirota, Y; Miyazaki, T; Nakamura, T; Niitani, H; Ohta, K; Suzuoki, Y; Tanaka, M; Yoshida, Y, 1990)	0.28
" The patient has been free of these symptoms on a dosage of 1500 mg cytarabine ocfosfate/day (cycle of 14 days with intervals of 14-21 days) for 24 months and remains in an ongoing partial remission."	( Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. Braess, J; Hiddemann, W; Kaeser-Fröhlich, A; Kaufmann, CC; Kern, W; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M, 1996)	0.29
" After administration of YNK01 at a dosage of 100-150 mg/m2 plasma levels of AraC were comparable to those achieved after low-dose AraC treatment (20 mg/m2) while at doses of YNK01 of 450-600 mg/m2 concentrations of standard-dose AraC (100 mg/m2) were obtained."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3
" Alternate dosing strategies may enhance the tolerability of YNK01."	( Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Arthur, C; Blacklock, H; Bradstock, K; Browett, P; Coulston, J; Gibson, J; Grigg, A; Hawkins, T; Herrmann, R; Hughes, T; Januszewicz, H; Low, C; Martin, N; Mollee, P; Morton, J; Rodwell, R; Schwarer, AP; Seldon, M; Seymour, JF; Shina, S; Spencer, A; Taylor, D; Taylor, KM; Watson, A; Wolf, M; Wright, S, 2004)	0.32
" Optimal dosing protocols for immunomodulation in dogs have not been defined."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13
" Application of functional and active metabolite assessment is feasible and may provide more relevant data to determine optimal dosing regimens for Ara-C-based treatments."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (3.64)	18.7374
1990's	41 (74.55)	18.2507
2000's	10 (18.18)	29.6817
2010's	2 (3.64)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	17 (29.82%)	5.53%
Reviews	2 (3.51%)	6.00%
Case Studies	21 (36.84%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (29.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
histamine [no description available]	1.99	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	1.97	1	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
hydroxyurea [no description available]	2.43	2	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	1.99	1	0	carbazoles
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	1.97	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	1.99	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
cytidine monophosphate Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. cytidine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.	10.88	55	17	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
cytarabine [no description available]	7.77	12	3	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
deoxycytidine [no description available]	3.09	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arabinofuranosylcytosine triphosphate Arabinofuranosylcytosine Triphosphate: A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.	1.97	1	0
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	1.97	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
etoposide [no description available]	5.56	6	3	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.09	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	1.98	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.38	2	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
2'-deoxy-2'-methylenecytidine [no description available]	3.09	1	0
arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.	3.37	1	1
nartograstim nartograstim: a mutein of recombinant human G-CSF	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Dysmyelopoietic Syndromes [description not available]	6.77	14	5
Acute Myelogenous Leukemia [description not available]	6.64	12	5
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	6.77	14	5
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	6.64	12	5
Chromosome Inversion An aberration in which a chromosomal segment is deleted and reinserted in the same place but turned 180 degrees from its original orientation, so that the gene sequence for the segment is reversed with respect to that of the rest of the chromosome.	2.47	2	0
Local Neoplasm Recurrence [description not available]	3.86	2	1
Granulocytic Leukemia, Chronic [description not available]	7.09	9	4
BOOP [description not available]	2.02	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	7.09	9	4
Recrudescence [description not available]	2.03	1	0
Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.	2.03	1	0
Dysarthosis [description not available]	2.03	1	0
Hyperesthesia Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.	2.03	1	0
Neutrophilic Leukemia, Chronic [description not available]	2.03	1	0
Leukemia, Neutrophilic, Chronic A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).	2.03	1	0
Monosomy The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as 2N-1.	2.39	2	0
Leukemia, Smoldering [description not available]	4.47	5	1
Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.	4.47	5	1
Adenocarcinoma, Basal Cell [description not available]	1.98	1	0
Cancer of Lung [description not available]	4.98	3	1
Cancer of Stomach [description not available]	1.98	1	0
Colorectal Cancer [description not available]	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	4.98	3	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	1.98	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1.98	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	4.34	2	2
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	4.34	2	2
Leukemia, Myeloid, Acute, M4 [description not available]	2.39	2	0
Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.	2.39	2	0
Leucocythaemia [description not available]	5.31	7	2
Acute Disease Disease having a short and relatively severe course.	5.67	7	3
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	5.31	7	2
Chromosomal Translocation [description not available]	1.98	1	0
Cancer, Second Primary [description not available]	1.98	1	0
Anterior Choroidal Artery Infarction [description not available]	1.98	1	0
Acute Onset Vascular Dementia [description not available]	1.98	1	0
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	1.98	1	0
Dementia, Vascular An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)	1.98	1	0
Granulocytic Leukemia [description not available]	3.78	2	1
Erythremia [description not available]	2.39	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	3.78	2	1
Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.	2.39	2	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.67	3	0
Experimental Leukemia [description not available]	2.38	2	0
Acute Promyelocytic Leukemia [description not available]	1.98	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	1.98	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	3.37	1	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	3.37	1	1
Hepatocellular Carcinoma [description not available]	4.34	2	2
Cancer of Liver [description not available]	4.34	2	2
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	4.34	2	2
Liver Neoplasms Tumors or cancer of the LIVER.	4.34	2	2
Carcinoma, Non-Small Cell Lung [description not available]	2.91	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.91	1	0
Eosinophilia, Tropical [description not available]	1.99	1	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	1.99	1	0
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	1.99	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.62	3	2
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	4.33	2	2
Leukocytopenia [description not available]	3.38	1	1
Thrombopenia [description not available]	3.38	1	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	3.38	1	1
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	4.33	2	2
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.38	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.38	1	1
Granulocytic Leukemia, Chronic, Stable Phase [description not available]	3.8	2	1
Blast Phase [description not available]	2.01	1	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	2.01	1	0
Chronic Illness [description not available]	1.97	1	0
Kahler Disease [description not available]	1.97	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	1.97	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	1.97	1	0
Leukemia L 1210 [description not available]	2.66	3	0
Emesis [description not available]	4.32	2	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	4.32	2	2
Experimental Neoplasms [description not available]	1.97	1	0

1-arabinofuranosylcytosine-5'-stearylphosphate

Description

Cross-References

Synonyms (5)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (55)

Study Types